"Precarity is the one constant of academic science. Themes of instability thread themselves through everything we do." A brief blog post from me about the @ukri.org funding pause and who the real victims will be. occamstypewriter.org/mindthegap/2... #AcademicSky

We are inviting applications for postdoctoral fellows in immunology of TB at the South African Tuberculosis Vaccine Initiative, University of Cape Town. For more information see the attached ad: idm.uct.ac.za/media/739223

👶✈️ Balancing caregiving and academic travel? Join Dr. Laura Pallett for "The Dual Demands of Academic Travel and Caregiving" 🗓️ Sept 25 | 🕒15:00 CEST 🔗https://tinyurl.com/yefis2025-ia2 Hosted by the Improving Academia group of yEFIS

In @elife.bsky.social: Type I interferon responses contribute to immune protection against mycobacterial infection doi.org/10.7554/eLif... #TBSky #IDSky #Immunosky work led by Gillian Tomlinson with support from @mnoursad.bsky.social & @innate2adaptive.bsky.social group (1/5)

Very excited to share our new piece of work in the Lancet Global Health @lancetgh.bsky.social – Periskope-CM, a set of personalised risk prediction tools for HIV-associated cryptococcal meningitis mortality: www.thelancet.com/journals/lan... #IDsky #HIV #GlobalHealth #meningitis #fungal 1/8

Come on down, anyone eligible for a post-doc do consider applying for this exciting project with @jennyrohn.bsky.social, @scottishwormboy.bsky.social & me! Got a touch of #UTISky #IDSky #ImmunoSky & 🧪 about it! 😉

Interested in T cell immunity in TB? Check out our new pre-print on antigen-agnostic identification of generalisable human in vivo Mtb-reactive T cell responses: www.biorxiv.org/content/10.1... with @qimmuno.bsky.social & @innate2adaptive.bsky.social

Dr Munyaradzi Musvosvi speaks about the Titan Vaccine Research Project which will allow selection of most promising TB vaccine candidates. This work is supported by the South African mRNA Vaccine Consortium & funded by @samrcza.bsky.social @tomscriba.bsky.social www.youtube.com/watch?v=zwPM...

Immunopathology of TB: SATVI researchers discuss a groundbreaking study which investigates the role of lymph nodes in the context of mycobacterium tuberculosis infection and disease. The study was funded by a grant from @wellcomeleap.bsky.social a program of youtu.be/8_gCOAfWUpw

2 weeks to the deadline for applications to this post.. take a look, get in touch if you want hear more, don't hold back😎

It's just under 1 month to World Immunisation Week 2025 (24th - 30th April)! Check the link below to read more about this crucial campaign for global health. www.who.int/campaigns/wo... #WorldImmunisationWeek #VaccinesWork #WHO

Academic Clinical Lecturer Posts in Infection now out: for people training in ID in UK & hold/imminently completing PhD. 2 posts @lshtm.bsky.social shorturl.at/EIUIz 1 at St Georges & 1 at Kings shorturl.at/8kDY3 If interested in @lshtm.bsky.social posts get in touch. UK ID people please share!!

We’re hiring! Looking for a laboratory post-doc fellow to help us disentangle protective and pathogenic T cells in TB, so we can stratify disease-risk after infection, and develop more effective vaccines. Interdisciplinary science in the heart of London. What's not to like? More here: bit.ly/4iIEiwu

This is a great initiative!

State of the art in the enigmatic and complex world of immunological determinants of TB👇

Best #Nikolaus 🎅! Our paper on how the 🫁 microenvironment can shape #innate immunity against #viruses is out @sciimmunology.bsky.social This was a herculean effort brilliantly led by @pauljbaker.bsky.social who singlehandedly established the model in the lab during the pandemic. 🧪 #Immunosky 1/9

Cool illustration how informative human challenge models can be! Here #SARSCoV2 challenge model has identified: 👉 insights into differential regulation of IFN-stimulated genes 👉 potential diagnostic biomarkers for early (MX1) & late (IFI27) viral infections #IDSky #ImmunoSky #COVID19 #MedSky 🧪

Also out now.. after peer review, our analysis of blood transcriptional biomarkers of acute respiratory viral infection leveraging the SARS-CoV-2 human challenge model: www.nature.com/articles/s41...

Reposting for anyone who hasn't clocked this paper yet- fab analysis by @gushamilton.bsky.social @gpollara.bsky.social and team - persuaded anti-IL6 unlikely to increase TB risk , and now need to test it's potential as therapeutic to reduce immunopath. What else can we infer about TB immunology?

exciting.. congratulations @gpollara.bsky.social @jennyrohn.bsky.social - look forward to hearing more about it